Oura Plans September IPO Targeting $16 Billion Valuation After Rapid Growth

Oura, the smart ring manufacturer with offices in San Francisco and Finland, reportedly plans to launch a U.S. initial public offering as early as next month. The company aims to raise up to $3 billion in a listing that would value the operation at more than $16 billion, according to Bloomberg. Existing investors are expected to offload a significant chunk of stock during the offering, marking an aggressive financial move for the wearable health brand.

The proposed $16 billion valuation represents an enormous jump from the $10.9 billion valuation Oura received last September when it closed an $875 million Series E round. That funding round attracted backing from Fidelity, ICONIQ, Whale Rock, and Atreides, joining earlier investors like Dexcom, The Chernin Group, Forerunner Ventures, Coatue, and Temasek. The aggressive valuation increase reflects the company’s rapid expansion and growing mainstream appeal beyond its original niche market.

Oura announced in May that it had filed confidentially for an IPO, setting the stage for this upcoming public debut. Chief Executive Officer Tom Hale recently disclosed the company’s impressive revenue trajectory, revealing it generated $500 million in revenue in 2024 and roughly $1 billion in 2025. The company expects to generate close to $2 billion in revenue in 2026, driven by international expansion and heavily integrated artificial intelligence coaching features, though detailed financials will become available once its S-1 filing goes public.

From Biohacking Niche to Mainstream Health Brand

The wearable device has undergone a significant transformation from its origins as a niche biohacking tool for tech executives. Oura has successfully evolved into a mainstream sleep-and-recovery brand, shipping over 5.5 million units since its inception across global markets. The more than 900-person company recently pushed deeper into preventative healthcare by introducing an AI chatbot alongside glucose monitoring and blood pressure research capabilities.

This strategic pivot mirrors moves made by competitors in the increasingly crowded wearables space. The company positions itself at the intersection of consumer health technology and preventative medicine, targeting users interested in comprehensive wellness tracking beyond simple step counting. Oura’s expansion into broader health metrics reflects the industry’s shift toward more sophisticated biometric monitoring and personalized health insights powered by artificial intelligence.

Fierce Competition in the Wearables Market

The hardware sector has grown increasingly crowded as major tech players and specialized startups compete for market share. Samsung launched the Galaxy Ring two years ago to capture the Android ecosystem, bringing the tech giant’s resources and distribution network into direct competition with Oura’s offering. The move signaled that smart rings had matured from experimental gadgets into viable consumer products worth investment from major manufacturers.

Oura’s most direct rival may be Whoop, the fitness band maker that has undergone its own reinvention in recent years. Once positioned as a performance tool for elite athletes and young men, Whoop spent the past year courting a much broader audience by layering in hormone tracking and blood-panel testing for perimenopause and thyroid health. The strategic pivot drove Whoop’s own valuation up to $10 billion back in March, demonstrating investor appetite for wearables that address comprehensive health concerns beyond athletic performance.

Legal Challenges Cast Shadow Over IPO Plans

Not all of Oura’s recent attention has been positive, as legal challenges threaten to complicate the company’s public market debut. A proposed class action lawsuit filed last week in San Francisco accuses Oura of misleading consumers about the accuracy of its sleep tracking features. The complaint alleges the company claims capabilities that exceed what its hardware can actually measure, creating potential liability issues ahead of increased public scrutiny that accompanies going public.

“Among other complaints in the filing, Oura is accused of not just claiming to measure a heartbeat or a temperature, but the exact stage of sleep the wearer is in-which in reality requires electrodes in the scalp and sensors on the eyes, as only a hospital or other clinical setting can do,” according to the lawsuit filing.

In a statement to TechCrunch sent over the weekend, an Oura spokesperson pushed back against claims in the suit, indicating the company plans to defend against them in the appropriate legal forum. The spokesperson emphasized that while Oura Ring is not a medical device or a substitute for a clinical sleep study, Oura’s sleep staging has been validated and compared favorably in multiple studies. The legal dispute highlights ongoing tensions around consumer health technology accuracy claims and regulatory standards for wellness devices that increasingly blur the line between consumer gadgets and medical equipment.

High-Stakes Market Entry

The timing of Oura’s IPO reflects both opportunity and risk in the current market environment. The company enters public markets at a moment when investor enthusiasm for health technology remains strong but scrutiny of profitability and unit economics has intensified. Oura’s ability to demonstrate sustainable revenue growth toward the $2 billion target will prove critical in justifying its premium valuation and attracting institutional investors beyond its existing venture backers.

The significant stock sale by existing investors signals both confidence in the company’s long-term prospects and a desire to realize returns after years of private market growth. How public market investors value Oura compared to its venture-backed peers will provide important signals about the broader wearables sector and investor appetite for hardware companies with recurring revenue models. The September timeline puts Oura ahead of potential competitors eyeing similar public market debuts, potentially allowing it to capture investor attention before market conditions shift.